This phase III trial is trying to understand whether it is safer and more effective to combine chemotherapy and targeted therapy for the treatment of mantle cell lymphoma, or to use targeted therapy alone, in patients who are not eligible for a stem cell transplant and have not received prior treatment .
This trial is treating patients with mantle cell lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
BeiGene Australia Pty Ltd
Eligible patients will be randomised to receive zanubrutinib (a targeted therapy) OR bendamustine (chemotherapy) in combination with rituximab for the treatment of their cancer. Zanubrutinib will be administered as two 80 mg capsules by mouth twice a day; bendamustine will be administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6; and rituximab will be administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More